These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21083172)

  • 1. New ultrasensitive detection technologies and techniques for use in microdosing studies.
    Lappin G; Wagner CC; Langer O; van de Merbel N
    Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
    Ings RM
    Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
    Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
    Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
    Bae SK; Shon JH
    Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
    Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
    Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerator mass spectrometry of small biological samples.
    Salehpour M; Forsgard N; Possnert G
    Rapid Commun Mass Spectrom; 2008 Dec; 22(23):3928-34. PubMed ID: 18980253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Sadiq MW; Salehpour M; Forsgard N; Possnert G; Hammarlund-Udenaes M
    Drug Metab Dispos; 2011 Feb; 39(2):174-9. PubMed ID: 21059857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive determination of a pharmaceutical compound and its metabolites in human plasma by ultra-high performance liquid chromatography-tandem mass spectrometry with on-line solid-phase extraction.
    Heinig K; Wirz T; Bucheli F; Monin V; Gloge A
    J Pharm Biomed Anal; 2011 Mar; 54(4):742-9. PubMed ID: 21051172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.
    Burt T; John CS; Ruckle JL; Vuong LT
    Expert Opin Drug Deliv; 2017 May; 14(5):657-672. PubMed ID: 27564533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo.
    Chen J; Garner RC; Lee LS; Seymour M; Fuchs EJ; Hubbard WC; Parsons TL; Pakes GE; Fletcher CV; Flexner C
    Clin Pharmacol Ther; 2010 Dec; 88(6):796-800. PubMed ID: 20981003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies.
    Kostiainen R; Kotiaho T; Kuuranne T; Auriola S
    J Mass Spectrom; 2003 Apr; 38(4):357-72. PubMed ID: 12717747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative determination of peptide drug in human plasma samples at low pg/ml levels using coupled column liquid chromatography-tandem mass spectrometry.
    Lövgren U; Johansson S; Jensen LS; Ekström C; Carlshaf A
    J Pharm Biomed Anal; 2010 Nov; 53(3):537-45. PubMed ID: 20456896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of polar drugs in human plasma with liquid chromatography-tandem mass spectrometry.
    Deng P; Chen X; Zhong D
    Bioanalysis; 2009 Apr; 1(1):187-203. PubMed ID: 21083196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantioselective quantification of chiral drugs in human plasma with LC-MS/MS.
    Liu K; Zhong D; Chen X
    Bioanalysis; 2009 Jun; 1(3):561-76. PubMed ID: 21083153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.